CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 52 enrolled
Drug / intervention
Enzalutamide +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01547299
NCT01547299Phase 2Completed
CompareCT.gov

A Randomized, Open-label, Phase 2 Study Of Mdv3100 As A Neoadjuvant Therapy For Patients Undergoing Prostatectomy For Localized Prostate Cancer

Pfizer·interventional·Posted Mar 7, 2012·Updated Oct 23, 2018

In Brief

A Phase 2 clinical trial evaluating Enzalutamide, Leuprolide, and 1 other intervention for Prostate Cancer. Completed, enrolled 52 participants across 4 sites in 2 countries.

Detailed Summary

The purpose of this study is to determine if enzalutamide is an effective therapy in treating localized prostate cancer prior to prostatectomy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesCanada, United States
CollaboratorsAstellas Pharma Inc, Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 7, 2012
Enrollment StartMar 31, 2012
Primary CompletionNov 30, 2013
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 14.3 years ago

Interventions

Enzalutamidedrug

Leuprolidedrug

Dutasteridedrug